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and, as pointed out by Landier and 
colleagues, public health relevance. 
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Deﬁ ning and targeting 
high-risk populations in 
Buruli ulcer
Authors’ reply
We thank Jordi Landier and colleagues 
for their comments about our recent 
Article in The Lancet Global Health.1 
In their work, Landier and coworkers 
generalise some of our observations 
on Buruli ulcer in Benin to those for 
Cameroon, the country that has the 
ﬁ fth highest prevalence of Buruli ulcer 
worldwide. Briefly, they make use 
of age and sex distribution from the 
Cameroon national census to show 
that patients aged 5–14 years were 
twice as likely to be aﬀ ected by Buruli 
ulcer as older individuals; and that boys 
were over-represented in individuals 
younger than 15 years, women were 
over-represented in patients aged 
15–50 years, and that men and women 
were equally represented in patients 
older than 50 years. They advocate the 
use of national census references to 
produce incidence rates and incidence 
rate ratios (IRRs), which they believe 
to be the proper way to draw valid 
conclusions.
We agree that this method is an 
appropriate way to assess whether 
Buruli ulcer is over-represented 
in children, but this issue was not 
central to our study. We also felt 
that the introduction of external 
data, the quality of which we cannot 
assess and which might not be 
relevant to areas where Buruli ulcer 
is endemic—ie, remote rural areas of 
tropical countries—could lead to bias. 
Nevertheless, our Article reports that 
the median age of the population in 
Benin in 2010 is signiﬁ cantly higher 
than the median age of our cohort,1 
leading to the same conclusion as the 
IRRs. Landier and colleagues also deﬁ ne 
elderly people as a high incidence 
group. We would be cautious about 
this conclusion because their report 
and others do not provide the number 
of patients in each age group to assess 
the uncertainty of their measure.2 
As an example, consideration of the 
low number of patients older than 
60 years in our study (one of the 
largest worldwide) enticed us not to 
draw conclusions in that age category. 
With respect to the variation of the 
sex ratio with age, we are mindful 
that the national census correction 
is correct but negligible, because the 
general population sex ratio does not 
diﬀ er from 1 in Benin, whatever the 
age group considered.3 Therefore, 
Landier and colleagues reach the same 
overall conclusions as us, an extremely 
valuable conﬁ rmation.
Landier and colleagues note, as 
we did, that unbalanced age-gender 
distribution among patients with 
Buruli ulcer had previously been 
reported. However, the reference they 
quote is misleading, because it does 
not identify differential incidence 
by sex before the age of 60 years.2 
The research group stated in a later 
2009 review that “there are no 
sex differences in disease instance 
among children and adults”,4 as did 
another independent review cited 
by Landier and colleagues.5 This is 
regrettable because this important 
issue of the variation of the sex 
ratio with age, although repeatedly 
reported in research articles on 
Buruli ulcer, has been disregarded 
or even denied by most authors of 
review papers4,5 (see discussion in our 
Article1 for details). This denial has 
far too long hampered the research 
on the causes of this age-dependent 
variation of the sex-ratio in Buruli 
ulcer, understanding of which will be 
of great physiopathological, clinical, 
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